PYXS — Pyxis Oncology Share Price
- $194.92m
- $37.89m
- 41
- 22
- 68
- 39
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 1.08 | ||
Price to Tang. Book | 1.24 | ||
Price to Free Cashflow | n/a | ||
Price to Sales | 12.29 | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -32.44% | ||
Return on Equity | -34.37% | ||
Operating Margin | -414.02% |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | 12.89 | n/a | n/a |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Pyxis Oncology, Inc. is a clinical-stage company focused on developing therapeutics to target difficult-to-treat cancers. The Company is building therapeutics that hold the potential for mono and combination therapies. Its clinical program portfolio includes PYX-201, PYX-106 and PYX-107. PYX-201, an antibody-drug conjugate (ADC) that targets Extradomain-B Fibronectin within the tumor stroma, and PYX-106, a fully human Siglec-15-targeting antibody designed to block suppression of T-cell proliferation and function, are being evaluated in ongoing Phase 1 clinical studies in multiple types of solid tumors. PYX-107 is a CD40 agonist antibody designed to maximize its agonistic properties. Its therapeutic candidates are designed to directly kill tumor cells and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Its ADC and immuno-oncology (IO) programs target a range of solid tumors resistant to current standards of care.
Directors
- Lara Sullivan CEO
- Pamela Connealy CFO (59)
- Ritu Shah COO
- Ronald Herbst CSO
- James Mutamba VBD
- Martina Molsbergen OTH (55)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- June 11th, 2018
- Public Since
- October 8th, 2021
- No. of Shareholders
- 62
- No. of Employees
- 51
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market
- Shares in Issue
- 58,888,473
![Blurred out image of a map](https://www.stockopedia.com/assets/conversion/images/maps_placeholder.jpg)
- Address
- 321 Harrison Avenue, 11th Floor, Suite 1, BOSTON, 02118
- Web
- https://pyxisoncology.com/
- Phone
- +1 6174533596
- Auditors
- Ernst & Young LLP
Latest News for PYXS
Upcoming Events for PYXS
Q2 2024 Pyxis Oncology Inc Earnings Release
Similar to PYXS
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
As of Today at 22:49 UTC, shares in Pyxis Oncology are trading at $3.37. This share price information is delayed by 15 minutes.
Shares in Pyxis Oncology last closed at $3.37 and the price had moved by +23.9% over the past 365 days. In terms of relative price strength the Pyxis Oncology share price has underperformed the S&P500 Index by -1.41% over the past year.
The overall consensus recommendation for Pyxis Oncology is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Pyxis Oncology does not currently pay a dividend.
Pyxis Oncology does not currently pay a dividend.
Pyxis Oncology does not currently pay a dividend.
To buy shares in Pyxis Oncology you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $3.37, shares in Pyxis Oncology had a market capitalisation of $198.45m.
Here are the trading details for Pyxis Oncology:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: PYXS
Based on an overall assessment of its quality, value and momentum Pyxis Oncology is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Pyxis Oncology is $8.83. That is 162.02% above the last closing price of $3.37.
Analysts covering Pyxis Oncology currently have a consensus Earnings Per Share (EPS) forecast of -$1.06 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Pyxis Oncology. Over the past six months, its share price has outperformed the S&P500 Index by +74.75%.
As of the last closing price of $3.37, shares in Pyxis Oncology were trading +3.78% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Pyxis Oncology PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $3.37.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Pyxis Oncology's management team is headed by:
- Lara Sullivan - CEO
- Pamela Connealy - CFO
- Ritu Shah - COO
- Ronald Herbst - CSO
- James Mutamba - VBD
- Martina Molsbergen - OTH